{"favorite_id": 10377, "calc_type": "", "dosing": false, "full_title_en": "Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus", "short_title_en": "IRAE for Endocrine Toxicities - Diabetes", "medium_description_en": "Grades severity of hyperglycemia secondary to immune checkpoint inhibitor therapy.", "short_description_en": "Hyperglycemia severity (ICPi therapy).", "before_use": "", "instructions_en": "<p><span id=\"docs-internal-guid-08a1bb22-7fff-3a1e-ff4d-b174ebcaf9d9\">Use in adult patients with signs and symptoms of new or worsening hyperglycemia that developed while on treatment with immune checkpoint inhibitors.</p>", "purpose_en": ["Diagnosis", "Prognosis"], "disease_en": ["Diabetes Mellitus", "Hyperglycemia"], "specialty_en": ["Allergy and Immunology", "Endocrinology", "Hospitalist Medicine", "Internal Medicine"], "chief_complaint_en": ["Fatigue", "Headache", "Weight Loss/Gain"], "system_en": ["Endocrine and Metabolic"], "search_abbreviation_en": ["Immune Related Adverse Events, irae, hyperglycemia, immune checkpoint inhibitor therapy, ICPi therapy, ASCO guideline, ASCO, Diabetes Mellitus, diabetes"], "slug": "immune-related-adverse-events-endocrine-toxicities-diabetes-mellitus", "seo": {"meta_description_en": "The Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus grades severity of hyperglycemia secondary to immune checkpoint inhibitor therapy.", "keywords_en": "Immune Related Adverse Events, irae, hyperglycemia, immune checkpoint inhibitor therapy, ICPi therapy, ASCO guideline, ASCO"}, "content": {"how_to_use": {"use_case_en": "<p><span id=\"docs-internal-guid-54e76422-7fff-66ab-c004-e9456b848f45\">Adult patients with signs and symptoms of new or worsening hyperglycemia that developed while on treatment with immune checkpoint inhibitors including agents against PD-1 (i.e., pembrolizumab, nivolumab), PD-L1 (i.e., atezolizumab, avelumab, durvalumab), or CTLA-4 (i.e., ipilimumab).</p>", "pearls_pitfalls_en": "<p><span id=\"docs-internal-guid-ada9f6d9-7fff-9a39-c396-3b7dbd370cd4\"></p>\n<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Immune checkpoint inhibitor (ICPi) related diabetes mellitus should be suspected in patients with laboratory evidence or signs and symptoms of new or worsening hyperglycemia while on treatment with immune checkpoint inhibitors.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">May occur at any time during immune checkpoint inhibitor treatment.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Type 2 diabetes mellitus is more frequent and presents with worsening glycemic control. Type 1 diabetes mellitus is rarely seen, frequently presents with diabetic ketoacidosis and could lead to life threatening consequences.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Distinguishing type 1 diabetes mellitus from type 2 diabetes mellitus is necessary.</p>\n</li>\n</ul>", "why_use_en": "<p><span id=\"docs-internal-guid-53bbc706-7fff-2e87-4862-8e64956901d9\">This tool aids in the decision to discontinue ICPi, further diagnostic work-up, and oral antidiabetic or insulin treatment initiation. </p>"}, "next_steps": {"advice_en": "<p><span id=\"docs-internal-guid-3e97d633-7fff-56c9-42a6-2fe4f5942f06\"></p>\n<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Monitor patients for hyperglycemia or other signs and symptoms of new or worsening diabetes mellitus, at baseline and with each treatment cycle during induction for 12 weeks, then every 3 to 6 weeks.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider a patient&rsquo;s medical background, exposure history, and risk factors for identification of diabetes mellitus type.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">If type 1 diabetes mellitus is suspected diagnostic work up should include anion gap and urine ketones etc. Anti&ndash;glutamic acid decarboxylase, anti&ndash;islet cell, or anti&ndash;insulin antibodies, insulin and C-peptide levels can assist in the diagnosis.</p>\n</li>\n</ul>", "management_en": "<p dir=\"ltr\">For all patients where an IRAE diagnosis is being considered, it is always recommended to involve the specialist or team prescribing the immune checkpoint therapy.&nbsp;</p>\n<p dir=\"ltr\"><strong>Grade 1:</strong></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">May continue ICPi with close clinical follow-up and laboratory evaluation.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider oral medications for those with new-onset type 2 diabetes mellitus.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Screen for T1DM if appropriate (i.e. acute onset with prior normal values or clinical concern for ketosis).</p>\n</li>\n</ol>\n<p dir=\"ltr\"><strong>Grade 2:</strong></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">May hold ICPi until serum glucose is controlled.&nbsp;</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">For worsening control in type 2 diabetes mellitus, titrate oral therapy consider insulin.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Administer insulin for type 1 diabetes mellitus or for patients whose diagnosis in question.&nbsp;</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Obtain urgent endocrine (preferred) or internal medicine consultation for patients with type 1 diabetes mellitus.&nbsp;</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Admission for patients with type 1 diabetes mellitus if ketoacidosis signs are present.</p>\n</li>\n</ol>\n<p dir=\"ltr\"><strong>Grade 3-4:</strong></p>\n<p><span id=\"docs-internal-guid-3ab2c604-7fff-8df4-ff3e-070e349dc36f\"></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Hold ICPi until toxicity recovers to grade &le;1.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Obtain urgent endocrine consultation.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Initiate insulin therapy.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Admit if there is concern for developing diabetic ketoacidosis, if the patient is symptomatic, if the patient with new onset type 1 diabetes mellitus is unable to see endocrinology.</p>\n</li>\n</ol>", "critical_actions_en": "<p dir=\"ltr\">Distinguishing type 1 diabetes mellitus from type 2 diabetes mellitus is necessary.&nbsp;</p>\n<p dir=\"ltr\">New onset hyperglycemia in a patient without risk factors of type 2 diabetes mellitus should raise concern for type 1 diabetes mellitus.</p>\n<p><span id=\"docs-internal-guid-456f0251-7fff-f114-5987-b3050d363382\"></p>\n<p dir=\"ltr\">Insulin is the treatment of choice for any patient where the diagnosis is in question.</p>"}, "about": {"formula_en": "<div dir=\"ltr\" align=\"left\">\n<table><colgroup><col /><col /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Criteria</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Hyperglycemia grade</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Asymptomatic or mild symptoms; fasting glucose value &gt;160 mg/dL (&gt;8.9 mmol/L); no evidence of ketosis or laboratory evidence of T1DM&nbsp;</p>\n</td>\n<td>\n<p dir=\"ltr\">G1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Moderate symptoms, able to perform ADLs, fasting glucose value &gt;160-250 mg/dL (&gt;8.9-13.9 mmol/L), ketosis or evidence of T1DM at any glucose level</p>\n</td>\n<td>\n<p dir=\"ltr\">G2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Severe symptoms, medically significant or life-threatening consequences, unable to perform ADLs; fasting glucose level &gt;250-500 mg/dL (&gt;13.9-27.8 mmol/L)&nbsp;</p>\n</td>\n<td>\n<p dir=\"ltr\">G3</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Severe symptoms, medically significant or life-threatening consequences, unable to perform ADLs; fasting glucose level &gt;500 mg/dL (&gt;27.8 mmol/L)&nbsp;</p>\n</td>\n<td>\n<p dir=\"ltr\">G4</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\">See Next Steps for details on management.</p>", "more_info_en": "", "evidence_based_medicine_en": "<p><span id=\"docs-internal-guid-b17ae4bf-7fff-cb28-d1af-d0df411f4538\">Guidelines for IRAE for endocrine toxicity (diabetes mellitus) were developed by a multidisciplinary, multi-organizational panel of experts in medical oncology based on a systematic review of the medical literature.</p>", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/29442540 ", "text": "Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768."}], "Other References": [], "Validation": [], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "", "firstName": "Nazli", "img": "", "lastName": "Dizman", "name": "Nazli Dizman, MD", "target": "", "signedCOI": true, "hasDisclosure": []}]}, "creator": [{"name": "Dr. Julie R. Brahmer", "qa_en": "", "approved": false, "creator_info": {"about_en": "<p>Julie R. Brahmer, MSc, MD, is the co-director of the upper aerodigestive department at Johns Hopkins Medicine in Baltimore, MD. She is also a professor of oncology at Johns Hopkins Medicine. Dr. Brahmer\u2019s primary research is focused on treatment of lung cancer and mesothelioma.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-julie-brahmer.png", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Brahmer+JR%5BAuthor%5D"}}], "reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "Criteria", "default": null, "conditionality": "", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "Asymptomatic or mild symptoms; fasting glucose value >160 mg/dL (>8.9 mmol/L); no evidence of ketosis or laboratory evidence of T1DM ", "value": 1}, {"label": "Moderate symptoms, able to perform ADLs, fasting glucose value >160-250 mg/dL (>8.9-13.9 mmol/L), ketosis or evidence of T1DM at any glucose level", "value": 2}, {"label": "Severe symptoms, medically significant or life-threatening consequences, unable to perform ADLs; fasting glucose level >250-500 mg/dL (>13.9-27.8 mmol/L) ", "value": 3}, {"label": "Severe symptoms, medically significant or life-threatening consequences, unable to perform ADLs; fasting glucose level >500 mg/dL (>27.8 mmol/L) ", "value": 4}], "name": "grading"}], "md5": "", "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "related_calcs": [{"calcId": 10382, "short_title_en": "IRAE for Endocrine Toxicities - Hypothyroidism", "slug": "immune-related-adverse-events-endocrine-toxicities-hypothyroidism"}, {"calcId": 10383, "short_title_en": "IRAE for Lung Toxicity - Pneumonitis", "slug": "immune-related-adverse-events-lung-toxicity-pneumonitis"}, {"calcId": 10378, "short_title_en": "IRAE for Renal Toxicities - Nephritis", "slug": "immune-related-adverse-events-renal-toxicities-nephritis"}]}